131I-angiostatin for transplanted Lewis lung carcinoma in mice

Qiu Ju Shao, Meng Hui Yuan, Hai Feng Xu, Fu Yang Li, Run Suo Zhou, Wang Feng Zhang, Jian Yang

Research output: Contribution to journalArticle

Abstract

Aim: To observe the radio-receptor imaging of 131I-angiostatin in C57BL/6 mice bearing Lewis lung cancer, evaluate the therapeutic effects of angiostatin, 131I-angiostatin and 131I on transplanted Lewis lung carcinoma in mice and investigate the clinical prospect of 131I-angiostatin for solid tumor. Methods: The imaging experiment was conducted in the laboratory for Nuclear Medicine, Tangdu Hospital, Fourth Military Medical University of Chinese PLA between February and May 2001. 1 Angiostatin was labeled with 131I by the conventional chloramines T(Ch-T) method. 131I-angiostatin was injected into C57BL/6 mice through caudal vein whose forelimbs were transplanted with Lewis lung carcinoma, and 131I labeled albumin(131I-Alb) as control. The whole body imaging was acquired at 24, 48, 96 and 144 hours after injection. 2 The treatment was conducted in the same laboratory as above from July 2002 to February 2003. Twenty-eight male C57BL/6 mice (the mean diameter of tumors transplanted into the right forelimbs was about 1 cm) whose forelimbs were transplanted with Lewis lung carcinoma were divided into four groups. Tumors in the four groups were treated with 131I-angiostatin(131I 11.1 MBq per mouse, angiostatin 12.5 mg/kg), angiostatin(12.5 mg/kg), 131I(11.1 MBq per mouse) respectively and with similar normal saline(NS) 0.3 mL as control. Each drug was given intraperitoneally and injected for two times at an interval of 7 days respectively. The volume of tumors was measured during 14 days after treatment. Results: After injection of 131I-angiostatin, 131I-angiostatin was distributed in whole body of mice during 48 hours of γ imaging, and the tumor showed clearly at 96 hours after injection at a highly specific concentration. The mean volume of transplanted tumors in the mice with Lewis lung cancer was (1 963 ± 126), (5 219 ± 351), (3 943 ± 236) and (7 353 ± 350) mm3 after treated with 131I-angiostatin, 131I, angiostatin and NS respectively, and the growth of transplanted Lewis lung carcinoma was inhibited by 73.3%, 46.4%, and 29.0% in the treatment groups respectively, significantly different from that in the control group(P = 0.000 3). Conclusion: 131I-angiostatin can highly and specifically concentrate in the tumor transplanted with Lewis lung carcinoma and can show the imaging of tumor tissues; It can also inhibit the growth of transplanted tumor of Lewis lung carcinoma in mice, and its inhibitive effect is better than that of 131I or angiostatin. So it is suggested that 131I-angiostatin has potential prospect of clinical application in the treatment of solid tumor.

Original languageEnglish (US)
Pages (from-to)124-125
Number of pages2
JournalChinese Journal of Clinical Rehabilitation
Volume9
Issue number14
StatePublished - Apr 14 2005

ASJC Scopus subject areas

  • Rehabilitation

Fingerprint Dive into the research topics of '<sup>131</sup>I-angiostatin for transplanted Lewis lung carcinoma in mice'. Together they form a unique fingerprint.

  • Cite this

    Shao, Q. J., Yuan, M. H., Xu, H. F., Li, F. Y., Zhou, R. S., Zhang, W. F., & Yang, J. (2005). 131I-angiostatin for transplanted Lewis lung carcinoma in mice. Chinese Journal of Clinical Rehabilitation, 9(14), 124-125.